Annexes

 

Chapter 1: Cardiovascular, Respiratory, and Related Disorders: Key Messages on Essential Interventions to Address its Burden in Low- and Middle-Income Countries

  • Annex 1A. Costing the Essential Package for Cardiovascular, Respiratory, and Related Disorders Notes 

 

Chapter 2: Relatonships Among Risk Factors and the Burden of Cardiovascular Diseases, Diabetes, and Chronic Lung Disease

  • Annex 2A. Updated Estimates of the Burden of CVRD in 2015

 

Chapter 5: Physical Activity for the Prevention of Cardiometabolic Disease

  • Annex 5A: Summary of Results on Direct Costs of Inactivity from 18 Studies between 1980–2014
  • Annex 5B: Tabulation of the Population Strategies and Interventions to Increase Physical Activity Levels at Multiple Levels of Interventions
  • Annex 5C: New Zealand’s Green Prescription (GRx)

 

Chapter 12: Diabetes: An Update on the Pandemic and Potential Solutions 

  • Annex 12A: Effectiveness and Quality of Evidence Regarding Diabetes Screening, Prevention, and Treatment Interventions
  • Annex 12B: Methodology for Cost-Effectiveness Analyses
  • Annex 12C: Studies Reporting Cost-Effectiveness of Diabetes Screening, Prevention, and Treatment Interventions
  • Annex 12D: Valuing Interventions—Regional Ceiling Ratios for Benchmarking
  • Annex 12E: Gathering and Analyzing Stakeholder Perspectives to Prioritize Interventions

 

Chapter 13: Kidney Disease

  • Annex 13A. Kidney Disease Improving Global Outcomes: Criteria for AKI Severity
  • Annex 13B. Kidney Disease Improving Global Outcomes: Stages of Chronic Kidney Disease
  • Annex 13C. Selected Population-Based Studies Reporting Prevalence of Chronic Kidney Disease

 

Chapter 17: Innovations in Community-Based Health for Cardiometabolic Diseases 

  • Annex 17A: Examples of Self-Management Interventions for Cardiometabolic Conditions in LMICs and the Evaluation of Their Effects

 

Chapter 18: Quality Improvement in Vascular Disease Care

  • Annex 18A. Systematic Review Methods and Complete Search Results

 

Chapter 19: Summary of Costs and Cost-Effectiveness of Interventions and Policies to Prevent and Treat Cardio-metabolic Diseases

  • Annex 19A. Methods, Framework, and Results